DSIP Quick Reference (5 mg vial)

Research context: mechanisms, human and preclinical evidence, limitations and precautions are in How this works and References. The calculator (Spanish) converts any other volume.
DSIP Dosage Chart (5 mg vial)
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (1 mL = ~5 mg/mL)
| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Week 1 | 100 mcg | 2 units (0.02 mL) |
| Week 2 | 150 mcg | 3 units (0.03 mL) |
| Week 3 | 200 mcg | 4 units (0.04 mL) |
| Weeks 4–8 | 300 mcg | 6 units (0.06 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Reconstitution Steps
- Draw 1 mL of bacteriostatic water with a sterile syringe.1
- Inject slowly down the vial wall; avoid shaking to prevent foaming.2
- Gently swirl or roll until fully dissolved (clear solution).3
- Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.4
Advanced / Extended Approach (1 mL = ~5 mg/mL)
| Week / phase | Daily dose | Units per injection (mL) |
|---|---|---|
| Week 5 | 400 mcg | 8 units (0.08 mL) |
| Weeks 6–8+ | 500 mcg | 10 units (0.10 mL) |
Frequency: Once daily, subcutaneously, at a consistent time.
Note: Amounts above 300 mcg come from anecdotal experience; formal human studies mainly used low body-weight-based doses.
The per-phase amounts are identical across the DSIP family. The 5 mg vial only changes the concentration, U-100 units, volume and supplies.
Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
U-100 Conversion Table (1 mL = 5 mg/mL)
| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 50 injections |
| 5 | 0.05 mL | 250 mcg | 20 injections |
| 10 | 0.10 mL | 500 mcg | 10 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 5 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 3 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 2 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 1 injection |
This section describes which dose a study or reference source used and what it measured. It is not a recommendation or an administration schedule. A trial dose belongs to its population, duration and supervision and does not transfer to anyone outside that context.
Supplies Needed
Straightforward 12- and 24-week planning for a 5 mg vial at 5 mg/mL.
DSIP vials (5 mg each)
- Standard / Gradual Approach, 12 weeks: Minimum 5 vials (22.05 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 10 vials (47.25 mg required).
U-100 syringes (1 mL)
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.
Bacteriostatic water
- Standard / Gradual Approach, 12 weeks: 5 mL total (1 mL per vial) → 2 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 10 mL total (1 mL per vial) → 4 × 3 mL vials.
Alcohol swabs
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
Sharps container: one appropriately sized. Stability planning: totals are minimum arithmetic quantities; follow the product documentation for sterility, storage, handling loss and discard timing.
DSIP 5mgView in store
Bacteriostatic water 3 mLView in storeStore links may earn a commission. A supplier page is not scientific evidence or proof of suitability for human use.
DSIP Vial and Research Context
- Reconstitute: add 1 mL of bacteriostatic water to produce 5 mg/mL.
- Frequency in the source: once daily, subcutaneously.
- Described range: schedules run from 100 mcg to 500 mcg per injection.
- Easy measuring: 1 U-100 unit = 0.01 mL = 50 mcg.
- Vial size: the 5 mg label is total nominal content, not a per-injection amount.
- Vial coverage: at 100 mcg per injection one vial supplies 50 injections; at 500 mcg it supplies 10. These are mass calculations, not storage periods.
Protocol Overview
Quick reference for the schedules shared by the cited literature.
- Frequency: once daily.
- Concentration: 5 mg in 1 mL = 5 mg/mL.
- Unit conversion: 1 U-100 unit = 50 mcg.
Dosing Schedule
The tables keep each approach separate.
- Standard / Gradual Approach: 100 mcg, 150 mcg, 200 mcg, 300 mcg, in phases (once daily).
- Advanced / Extended Approach: 400 mcg, 500 mcg, in phases (once daily).
- Measurement: use the units and mL shown beside each amount.
- Consistency: vial size does not change the schedule.
Storage Instructions
- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.
More detail in the storage guide (Spanish).
Important Notes
- Research only: the referenced compounds are sold for laboratory research. Nothing here is medical advice or an administration schedule.
- Above 100 units: a 1 mL U-100 syringe cannot hold them; split across syringes or reconstitute with less volume.
- Accuracy: concentration depends on the actual volume added; measure the diluent with a syringe, not by eye.
- Verification: confirm vial contents against the batch certificate of analysis before calculating.
How This Works
- Hypothalamic-pituitary-adrenal axis modulation In research literature, a reduction in nocturnal cortisol release has been documented, associated with deeper sleep in models
- Increased cerebral adenosine: boost sleep homeostatic pressure
- Neurotransmitter Regulation balances acetylcholine, GABA, and glutamate in patterns favorable to deep sleep
- Endogenous antioxidant reduce neuronal oxidative stress accumulated during wakefulness
- Without direct action on melatonin or benzodiazepine receptors: Mechanism other than pharmaceutical hypnotics
Research Applications
- Chronic insomnia research, particularly deep sleep maintenance
- Studies on jet lag and circadian rhythm disorders
- Research in chronic fatigue syndrome
- Post-exercise recovery studies in high-performance models
- Chronic stress modulation research (via nocturnal cortisol suppression)
- Studies on sleep quality in abstinence contexts
- Preliminary studies in chronic migraine
Precautions Described in the Literature
In the research literature, DSIP presents a pharmacological profile described as benign: as an endogenous peptide, studies report no tolerance, dependence, or withdrawal syndrome in the evaluated models. Store lyophilized under refrigeration and, once reconstituted, protected from light.
Studied Combinations
- Sleep line + stress: DSIP along with Selank in nocturnal modulation studies
- Recovery line GH pulse research with DSIP, CJC No DAC, and Ipamorelin
- Cognitive line DSIP with Semax in day/night rhythm studies
Injection Technique in Research
- Route in the studies: subcutaneous, in abdominal or thigh adipose tissue, rotating the site.
- Syringe: 1 mL U-100 (100 units); read in units, not mL.
- Asepsis: alcohol swab on the stopper and the site; a new syringe per injection.
- Drawing: purge air, draw the units from the chart and verify before withdrawing the needle from the vial.
Full guide: U-100 syringes and reading units (Spanish).
Research Note
All content on this page is technical and educational. It describes how a vial is reconstituted, how a syringe is read and which amounts the cited sources describe. It does not replace the supervision of a qualified researcher or the judgment of a health professional, and it is not intended to diagnose, treat, cure or prevent any disease.
References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci USA. 1977;74(3):1282-1286.
- Graf MV, Kastin AJ. Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev. 1984;8(1):83-93.
- Sudakov KV, Ivanov VT, Koplik EV, et al. Delta-sleep inducing peptide (DSIP) as a factor facilitating animals’ resistance to acute emotional stress. Pavlov J Biol Sci. 1983;18(1):1-5.